Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation.

Vella V, Nicolosi ML, Giuliano M, Morrione A, Malaguarnera R, Belfiore A.

Cells. 2019 Sep 1;8(9). pii: E1017. doi: 10.3390/cells8091017.

2.

Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection.

Vella V, Malaguarnera R, Nicolosi ML, Morrione A, Belfiore A.

Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118522. doi: 10.1016/j.bbamcr.2019.118522. Epub 2019 Aug 5. Review.

PMID:
31394114
3.

The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives.

Vella V, Malaguarnera R.

Int J Mol Sci. 2018 Nov 30;19(12). pii: E3814. doi: 10.3390/ijms19123814. Review.

4.

DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.

Vella V, Nicolosi ML, Cantafio P, Massimino M, Lappano R, Vigneri P, Ciuni R, Gangemi P, Morrione A, Malaguarnera R, Belfiore A.

Endocr Relat Cancer. 2019 Jan 1;26(1):197-214. doi: 10.1530/ERC-18-0310.

PMID:
30121624
5.

Editorial: Clinical and Molecular Epidemiology of Thyroid Cancer of Follicular Origin.

Malaguarnera R, Vella V, Pellegriti G, Belfiore A.

Front Endocrinol (Lausanne). 2018 Mar 12;9:67. doi: 10.3389/fendo.2018.00067. eCollection 2018. No abstract available.

6.

A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer.

Belfiore A, Malaguarnera R, Nicolosi ML, Lappano R, Ragusa M, Morrione A, Vella V.

Cell Adh Migr. 2018;12(4):305-314. doi: 10.1080/19336918.2018.1445953. Epub 2018 Mar 23. Review.

7.

Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?

Malaguarnera R, Vella V, Nicolosi ML, Belfiore A.

Front Endocrinol (Lausanne). 2017 Nov 14;8:314. doi: 10.3389/fendo.2017.00314. eCollection 2017. Review.

8.

Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Belfiore A, Malaguarnera R, Vella V, Lawrence MC, Sciacca L, Frasca F, Morrione A, Vigneri R.

Endocr Rev. 2017 Oct 1;38(5):379-431. doi: 10.1210/er.2017-00073. Review.

9.

The lauric acid-activated signaling prompts apoptosis in cancer cells.

Lappano R, Sebastiani A, Cirillo F, Rigiracciolo DC, Galli GR, Curcio R, Malaguarnera R, Belfiore A, Cappello AR, Maggiolini M.

Cell Death Discov. 2017 Sep 18;3:17063. doi: 10.1038/cddiscovery.2017.63. eCollection 2017.

10.

Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.

Vella V, Malaguarnera R, Nicolosi ML, Palladino C, Spoleti C, Massimino M, Vigneri P, Purrello M, Ragusa M, Morrione A, Belfiore A.

Oncotarget. 2017 Jun 27;8(26):43248-43270. doi: 10.18632/oncotarget.18020.

11.

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.

Vella V, Nicolosi ML, Giuliano S, Bellomo M, Belfiore A, Malaguarnera R.

Front Endocrinol (Lausanne). 2017 Feb 22;8:31. doi: 10.3389/fendo.2017.00031. eCollection 2017. Review.

12.

Recent advances on the stimulatory effects of metals in breast cancer.

Lappano R, Malaguarnera R, Belfiore A, Maggiolini M.

Mol Cell Endocrinol. 2017 Dec 5;457:49-56. doi: 10.1016/j.mce.2016.10.017. Epub 2016 Oct 17. Review.

PMID:
27765682
13.

Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer.

Vella V, Malaguarnera R, Lappano R, Maggiolini M, Belfiore A.

Mol Cell Endocrinol. 2017 Dec 5;457:57-72. doi: 10.1016/j.mce.2016.10.020. Epub 2016 Oct 20. Review.

PMID:
27773847
14.

IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.

Matà R, Palladino C, Nicolosi ML, Lo Presti AR, Malaguarnera R, Ragusa M, Sciortino D, Morrione A, Maggiolini M, Vella V, Belfiore A.

Oncotarget. 2016 Feb 16;7(7):7683-700. doi: 10.18632/oncotarget.6524.

15.

Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features.

Gianì F, Vella V, Nicolosi ML, Fierabracci A, Lotta S, Malaguarnera R, Belfiore A, Vigneri R, Frasca F.

J Clin Endocrinol Metab. 2015 Sep;100(9):E1168-78. doi: 10.1210/JC.2014-4163. Epub 2015 Jul 7.

PMID:
26151334
16.

Novel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses.

Malaguarnera R, Nicolosi ML, Sacco A, Morcavallo A, Vella V, Voci C, Spatuzza M, Xu SQ, Iozzo RV, Vigneri R, Morrione A, Belfiore A.

Oncotarget. 2015 Jun 30;6(18):16084-105.

17.

Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells.

De Marco P, Cirillo F, Vivacqua A, Malaguarnera R, Belfiore A, Maggiolini M.

Front Endocrinol (Lausanne). 2015 Mar 6;6:30. doi: 10.3389/fendo.2015.00030. eCollection 2015. Review.

18.

Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.

Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K.

Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21.

19.

Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.

20.

GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts.

De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, Pezzi V, Belfiore A, Maggiolini M.

Endocr Relat Cancer. 2014 Oct;21(5):739-53. doi: 10.1530/ERC-14-0245. Epub 2014 Jul 10.

PMID:
25012984
21.

Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells.

Piro S, Mascali LG, Urbano F, Filippello A, Malaguarnera R, Calanna S, Rabuazzo AM, Purrello F.

PLoS One. 2014 Feb 28;9(2):e90093. doi: 10.1371/journal.pone.0090093. eCollection 2014.

22.

The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.

Malaguarnera R, Belfiore A.

Front Endocrinol (Lausanne). 2014 Feb 4;5:10. doi: 10.3389/fendo.2014.00010. eCollection 2014. Review.

23.

Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.

Malaguarnera R, Sacco A, Morcavallo A, Squatrito S, Migliaccio A, Morrione A, Maggiolini M, Belfiore A.

Endocrinology. 2014 Apr;155(4):1207-21. doi: 10.1210/en.2013-1925. Epub 2014 Jan 17.

24.

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.

Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A.

Int J Mol Sci. 2013 Nov 20;14(11):22933-66. doi: 10.3390/ijms141122933. Review.

25.

In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.

Mazza A, Fruci B, Guzzi P, D'Orrico B, Malaguarnera R, Veltri P, Fava A, Belfiore A.

Nutr Metab Cardiovasc Dis. 2014 Feb;24(2):132-9. doi: 10.1016/j.numecd.2013.04.016. Epub 2013 Jul 8.

PMID:
23845740
26.

The insulin and igf-I pathway in endocrine glands carcinogenesis.

Malaguarnera R, Morcavallo A, Belfiore A.

J Oncol. 2012;2012:635614. doi: 10.1155/2012/635614. Epub 2012 Aug 8.

27.

Thyroid cancer development and progression: emerging role of cancer stem cells.

Malaguarnera R, Morcavallo A, Giuliano S, Belfiore A.

Minerva Endocrinol. 2012 Jun;37(2):103-15. Review.

PMID:
22691885
28.

New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer.

Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M.

Cell Signal. 2012 Aug;24(8):1515-21. doi: 10.1016/j.cellsig.2012.03.012. Epub 2012 Mar 28. Review.

PMID:
22481093
29.

Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway.

Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A.

Endocrinology. 2012 May;153(5):2152-63. doi: 10.1210/en.2011-1843. Epub 2012 Feb 21.

PMID:
22355074
30.

The role of metformin in the management of NAFLD.

Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A.

Exp Diabetes Res. 2012;2012:716404. doi: 10.1155/2012/716404. Epub 2011 Dec 12. Review.

31.

Insulin receptor and cancer.

Belfiore A, Malaguarnera R.

Endocr Relat Cancer. 2011 Jul 4;18(4):R125-47. doi: 10.1530/ERC-11-0074. Print 2011 Aug. Review.

PMID:
21606157
32.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108. Epub 2011 Jan 10.

33.

The insulin receptor: a new target for cancer therapy.

Malaguarnera R, Belfiore A.

Front Endocrinol (Lausanne). 2011 Dec 6;2:93. doi: 10.3389/fendo.2011.00093. eCollection 2011.

34.

Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid.

Malaguarnera R, Frasca F, Garozzo A, Gianì F, Pandini G, Vella V, Vigneri R, Belfiore A.

J Clin Endocrinol Metab. 2011 Mar;96(3):766-74. doi: 10.1210/jc.2010-1255. Epub 2010 Dec 1.

PMID:
21123448
35.

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Belfiore A, Genua M, Malaguarnera R.

PPAR Res. 2009;2009:830501. doi: 10.1155/2009/830501. Epub 2009 Jul 7.

36.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

37.

TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.

Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, Frasca F.

Mol Cancer Res. 2008 Jan;6(1):64-77. doi: 10.1158/1541-7786.MCR-07-0005.

38.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

39.

Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling.

Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, Belfiore A, Vigneri R.

J Biol Chem. 2007 Sep 7;282(36):26077-88. Epub 2007 Jul 9.

40.

p53 family proteins in thyroid cancer.

Malaguarnera R, Vella V, Vigneri R, Frasca F.

Endocr Relat Cancer. 2007 Mar;14(1):43-60. Review.

PMID:
17395974
41.

HMGA1 inhibits the function of p53 family members in thyroid cancer cells.

Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, Giancotti V, Pezzino V, Vigneri R, Manfioletti G.

Cancer Res. 2006 Mar 15;66(6):2980-9.

42.

The p53-homologue p63 may promote thyroid cancer progression.

Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, Vigneri P, Aloisi A, Vigneri R, Frasca F.

Endocr Relat Cancer. 2005 Dec;12(4):953-71.

PMID:
16322335

Supplemental Content

Loading ...
Support Center